Disease Expression in Autosomal Recessive Retinal Dystrophy Associated With Mutations in the DRAM2 Gene.

PURPOSE To determine the disease course of retinal dystrophy caused by recessive variants in the DRAM2 (damage-regulated autophagy modulator 2) gene. METHODS Sixteen individuals with DRAM2-retinopathy were examined (six families; age range, 19-56 years, includes one pre-symptomatic case). The change in visual acuity over time was studied, and electrophysiology (n = 6), retina-tracking perimetry (n = 1), fundus autofluorescence (FAF) imaging (n = 6), and optical coherence tomography (OCT; n = 12) were performed. RESULTS All symptomatic patients presented with central visual loss (15/15) unaccompanied either by nyctalopia or light-hypersensitivity; most (11/15) developed symptoms in the third decade of life. A granular macular appearance, often with associated white/yellow dots, was an early fundoscopic feature. There was an ill-defined ring of hyperautofluorescence on FAF. Optical coherence tomography revealed loss of the ellipsoid zone perifoveally in a 19-year-old pre-symptomatic individual. The central atrophic area enlarged over time and fundoscopy showed peripheral degeneration in seven of the nine individuals that were examined ≥ 10 years after becoming symptomatic; some of these subjects developed nyctalopia and light hypersensitivity. Electrophysiology revealed generalized retinal dysfunction in three of the five individuals that were tested ≥ 10 years after becoming symptomatic. CONCLUSIONS Patients with DRAM2-retinopathy are typically asymptomatic in the first two decades of life and present with central visual loss and a maculopathy. A faint hyperautofluorescent ring on FAF can be a suggestive feature. The retinal periphery is frequently affected later in the disease process. Photoreceptor degeneration is likely to be the primary event and future studies on DRAM2-retinopathy are expected to provide important insights into retinal autophagy.

[1]  Colin A. Johnson,et al.  Biallelic mutations in the autophagy regulator DRAM2 cause retinal dystrophy with early macular involvement. , 2015, American journal of human genetics.

[2]  Angeleen Fleming,et al.  Compromised autophagy and neurodegenerative diseases , 2015, Nature Reviews Neuroscience.

[3]  Q. Nguyen,et al.  One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis. , 2015, Translational vision science & technology.

[4]  M. Marmor,et al.  Hydroxychloroquine and the retina. , 2015, JAMA.

[5]  P. Sieving,et al.  Subjective and objective screening tests for hydroxychloroquine toxicity. , 2015, Ophthalmology.

[6]  S. Tsang,et al.  Quantitative fundus autofluorescence distinguishes ABCA4-associated and non-ABCA4-associated bull's-eye maculopathy. , 2015, Ophthalmology.

[7]  M. Westerfield,et al.  Non-manifesting AHI1 truncations indicate localized loss-of-function tolerance in a severe Mendelian disease gene. , 2015, Human molecular genetics.

[8]  Michael Bach,et al.  ISCEV Standard for full-field clinical electroretinography (2015 update) , 2014, Documenta Ophthalmologica.

[9]  A. Dillin,et al.  The role of protein clearance mechanisms in organismal ageing and age-related diseases , 2014, Nature Communications.

[10]  A. Fulton,et al.  Panel-based Genetic Diagnostic Testing for Inherited Eye Diseases is Highly Accurate and Reproducible and More Sensitive for Variant Detection Than Exome Sequencing , 2014, Genetics in Medicine.

[11]  Lei Shang,et al.  Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants , 2014, Proceedings of the National Academy of Sciences.

[12]  Lorenzo Galluzzi,et al.  Metabolic control of cell death , 2014, Science.

[13]  C. Klaver,et al.  Causes and consequences of inherited cone disorders , 2014, Progress in Retinal and Eye Research.

[14]  Colin A. Johnson,et al.  Mutation Screening of Retinal Dystrophy Patients by Targeted Capture from Tagged Pooled DNAs and Next Generation Sequencing , 2014, PloS one.

[15]  C. Mitchell,et al.  Autophagy in the eye: implications for ocular cell health. , 2014, Experimental eye research.

[16]  Monkol Lek,et al.  Biallelic variants in TTLL5, encoding a tubulin glutamylase, cause retinal dystrophy. , 2014, American journal of human genetics.

[17]  D. Zacks,et al.  Circadian and noncircadian modulation of autophagy in photoreceptors and retinal pigment epithelium. , 2014, Investigative ophthalmology & visual science.

[18]  D. G. MacArthur,et al.  Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.

[19]  Taichi Hara,et al.  Fluorescence-based visualization of autophagic activity predicts mouse embryo viability , 2014, Scientific Reports.

[20]  Valentina Cipriani,et al.  Natural history and retinal structure in patients with Usher syndrome type 1 owing to MYO7A mutation. , 2014, Ophthalmology.

[21]  Eric H. Baehrecke,et al.  Self-consumption: the interplay of autophagy and apoptosis , 2014, Nature Reviews Molecular Cell Biology.

[22]  D. Green,et al.  Autophagy and phagocytosis converge for better vision , 2014, Autophagy.

[23]  W. Hait,et al.  Therapeutic Targeting of Autophagy in Disease: Biology and Pharmacology , 2013, Pharmacological Reviews.

[24]  D. Green,et al.  Noncanonical Autophagy Promotes the Visual Cycle , 2013, Cell.

[25]  K. Tsubota,et al.  A longitudinal study of stargardt disease: clinical and electrophysiologic assessment, progression, and genotype correlations. , 2013, American journal of ophthalmology.

[26]  I. Jang,et al.  The expression of damage-regulated autophagy modulator 2 (DRAM2) contributes to autophagy induction , 2012, Molecular Biology Reports.

[27]  Sun-Mi Park,et al.  Reduced expression of DRAM2/TMEM77 in tumor cells interferes with cell death. , 2009, Biochemical and biophysical research communications.

[28]  K. Ryan,et al.  Analysis of DRAM-related proteins reveals evolutionarily conserved and divergent roles in the control of autophagy , 2009, Cell cycle.

[29]  A. J. Roman,et al.  ABCA4 disease progression and a proposed strategy for gene therapy. , 2009, Human molecular genetics.

[30]  Mary A. Johnson,et al.  ISCEV standard for clinical pattern electroretinography (PERG): 2012 update , 2007, Documenta Ophthalmologica.

[31]  F. Ferris,et al.  Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial. , 2014, Investigative ophthalmology & visual science.